Hem › Multipelt myelom › North Carolina › Charlotte
Kliniska studier för Multipelt myelom i Charlotte, NC
21 studier för Multipelt myelom söker deltagare vid platser i och runt Charlotte (inom ca 30 miles). Öppna en studie för att se vem som kan delta och hur du kontaktar studieteamet.
Officiell studietext (engelska)
Rekryterar du till en studie? Visa den högst upp på sidan – $99 i 30 dagar →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
RekryterarFas 3
- Research Site, Charlotte
- Research Site, Charlotte
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
RekryterarFas 1
- Levine Cancer Institute, Charlotte
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
RekryterarFas 4
- Levine Cancer Institute, Charlotte
A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
RekryterarFas 2
- Atrium Health, Charlotte
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
RekryterarFas 3
- Levine Cancer Institute, Charlotte
- Novant Health, Charlotte
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
RekryterarFas 1/2
- Atrium Health Levine Cancer Institute, Charlotte
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
RekryterarFas 2
- Atrium Health's Levine Cancer Institute, Charlotte
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
RekryterarFas 3
- Levine Cancer Institute, Charlotte
- Levine Cancer Institute, Charlotte
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RekryterarFas 1/2
- Atrium Health Levine Cancer Institute /ID# 271510, Charlotte
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
RekryterarFas 3
- Novant Health Cancer Institute, Charlotte
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
RekryterarFas 1
- Atrium Health, Levine Cancer Institute, Charlotte
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
RekryterarFas 1/2
- Research Site, Charlotte
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
RekryterarFas 3
- Research Site, Charlotte
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
RekryterarFas 1/2
- Atrium Health Levine Cancer Institute /ID# 276193, Charlotte
CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study
RekryterarObservationsstudieFriska volontärer välkomna
- Atrium Health Levine Cancer, Charlotte
Pre-malignant States to Hematologic Malignancies in Firefighters
RekryterarObservationsstudieFriska volontärer välkomna
- Levine Cancer Institute, Charlotte
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
RekryterarFas 3
- Levine Cancer Institute, Charlotte
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RekryterarFas 2
- Levine Cancer Institute, Charlotte
A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment
RekryterarFas 1/2
- Levine Cancer Institute, Charlotte
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
RekryterarFas 3
- GSK Investigational Site, Charlotte
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
RekryterarFas 1
- Levine Cancer Institute, Charlotte
Multipelt myelom-studier i andra städer
- New York City, NY60 studier
- Boston, MA42 studier
- Atlanta, GA42 studier
- Houston, TX38 studier
- Durham, NC37 studier
- Nashville, TN32 studier
- Denver, CO27 studier
- Rochester, MN24 studier
- St. Louis, MO24 studier
- Columbus, OH24 studier
- Baldwin Park, CA23 studier
- Edison, NJ22 studier
Andra studier i Charlotte
- Cancer (alla typer)27 studier
- Bröstcancer22 studier
- Icke-småcellig lungcancer19 studier
- Akut myeloid leukemi16 studier
- Övervikt16 studier
- Övervikt15 studier
- Kolorektal cancer13 studier
- Äggstockscancer12 studier
- Hjärtsvikt11 studier
- Metastaserande cancer11 studier
- Plattenepitelcancer i huvud och hals10 studier
- KOL9 studier
Från ClinicalTrials.gov, data hämtad 6 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.